Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center-Reference-Cited by-同舟云学术

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Published:2018-01-30 Issue:3 Volume:6 Page:288-294
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Lisberg Aaron,Tucker D. Andrew,Goldman Jonathan W.,Wolf Brian,Carroll James,Hardy Ariana,Morris Karolyn,Linares Paulina,Adame Carlos,Spiegel Marshall L.,Wells Courtney,McKenzie Jordan,Ledezma Blanca,Mendenhall Melody,Abarca Phillip,Bornazyan Krikor,Hunt Jaime,Moghadam Nima,Chong Natalie,Nameth Danielle,Marx Caitlin,Madrigal John,Vangala Sitaram,Shaverdian Narek,Elashoff David,Garon Edward B.

Funder

One Ball Matt Memorial Golf Tournament

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15

3. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

4. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review;Clinical and Translational Oncology;2024-04-24

5. Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer;Heliyon;2024-03